JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Breaking the Silence of Alzheimer's: A Modern Synthesis of Mechanisms, Markers, and Management

[1]Kuldeep Kaur,[2]Jatin Sharma, [3]Neha Sharma,[4]Dr. Lovkesh Bhatia
[12]UG Scholar,[3]Associate Professor,[4]Professor
[1234]Bharat Institute Of Pharmacy Degree Course, Kurukshetra, Haryana-136132

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder that gradually impairs memory, reasoning, and daily functioning. It is the leading cause of dementia worldwide, primarily affecting older adults, and its prevalence continues to rise with the aging population. Despite decades of research, a definitive cure remains elusive. However, breakthroughs in understanding the disease's molecular and clinical features have led to early diagnostic tools and novel treatment strategies.

This review offers a comprehensive overview of Alzheimer's disease, starting with its history, rising global burden, and associated risk factors—both modifiable and non-modifiable. It explores the underlying pathophysiological mechanisms, including amyloid plaques, tau tangles, neuroinflammation, and oxidative stress, which disrupt brain function and contribute to cognitive decline. Clinical stages from preclinical to severe Alzheimer's are discussed, highlighting how symptoms evolve over time.

We also examine current diagnostic techniques and biomarkers, such as brain imaging and cerebrospinal fluid analysis, which allow earlier and more accurate detection. Therapeutic approaches are classified into symptomatic treatments, disease-modifying drugs, and nonpharmacological interventions aimed at improving quality of life. In addition, lifestyle-based preventive strategies—like physical activity, diet, and cognitive engagement—are gaining attention for reducing disease risk.

Looking ahead, the future of Alzheimer's care lies in personalized medicine, emerging immunotherapies, and AI-driven technologies for early prediction and remote monitoring. By organizing this knowledge in a clear and accessible format, the review aims to promote awareness, encourage early diagnosis, and support compassionate care for those affected.

Keywords:

Alzheimer's disease; Dementia; Neurodegeneration; Amyloid-beta; Tau protein; Cognitive decline; Biomarkers; Disease-modifying therapies; Neuroinflammation; Lifestyle interventions

1. Background / Introduction

Alzheimer's disease is a *progressive* brain disorder that slowly destroys **memory**, **thinking ability**, and eventually, the ability to carry out the *simplest tasks*.[1] It is the **most common** form of dementia and mainly affects **older adults**, although some younger individuals may also develop it.[2] As the disease progresses, individuals lose the ability to **communicate**, **recognize loved ones**, or **care for themselves**, making it one of the most *emotionally* and *physically draining* conditions for both patients and caregivers.

The condition was first identified in **1906** by **Dr. Alois Alzheimer**, a German psychiatrist.[4] He studied the brain of a woman named **Auguste Deter** who had shown severe memory loss and behavioral changes.[5] After her death, Dr. Alzheimer found unusual protein clumps (later called **amyloid plaques**) and twisted fibers (now known as **tau tangles**) in her brain.[6] These features remain the core **pathological markers** of the disease even today.[7]

Globally, Alzheimer's disease has become a major **public health concern**.[8] It is estimated that **millions** of people are affected, with numbers expected to rise dramatically in the coming decades due to **aging populations**.[9] The disease not only places a heavy *emotional toll* on families but also leads to enormous **financial costs** for healthcare systems.[10] Unfortunately, despite years of research, a **complete cure** remains out of reach, and available treatments mainly focus on *relieving symptoms* for a limited time.[11]



Figure 1: Projected global increase in the number of people living with Alzheimer's disease between 2000 and 2050. The number of cases is expected to rise from approximately 26 million in 2000 to over 150 million by 2050, reflecting the growing burden of neurodegenerative disorders worldwide**.**

Recent advancements in science have helped researchers understand more about how Alzheimer's develops and progresses.[12] There is growing interest in finding new ways to **detect the disease early**, possibly even *before symptoms appear*. [13] At the same time, scientists are testing a variety of drugs that may help **slow** or **stop** the underlying brain changes.[15] *Inflammation*, *oxidative stress*, and *mitochondrial dysfunction* are now recognized as important contributors to the disease process, in addition to the classic **amyloid** and **tau** pathways.

This review aims to provide a *complete* and *simplified* overview of Alzheimer's disease. It will explore the major **risk factors**, **pathological mechanisms**, **clinical features**, **diagnostic tools**, **available treatments**, and **ongoing research**.[16] By organizing current knowledge in a clear format, this review hopes to support *awareness*, *early detection*, and improved care for individuals affected by this **devastating condition**.[17]

2. Epidemiology and Risk Factors

Alzheimer's disease is the most **common cause** of dementia, accounting for nearly *60 to 80%* of all cases.[18] As the **global population ages**, this condition has become an *urgent public health issue*. Currently, **over 50 million** people

are living with dementia worldwide, and this number is expected to **triple by 2050** due to longer life expectancy and declining birth rates.[19]

Age is the strongest known *non-modifiable* risk factor. After the age of 65, the risk of developing Alzheimer's **doubles every five years**.[20] By the age of 85, nearly **one-third** of individuals may be affected. **Women** are more likely to develop Alzheimer's than men, partly because they tend to live longer and may also be biologically more vulnerable to certain brain changes.[21]

Although most cases are **sporadic** with no clear inherited pattern, a small percentage — around *1%* — are **familial** and caused by specific gene mutations. These cases typically develop at a **younger age** and are linked to mutations in the **APP**, **PSEN1**, and **PSEN2** genes.[22] In the more common **late-onset** form, a major genetic risk factor is the presence of the **APOE ε4** allele.[23] Individuals with one copy of this gene variant have an increased risk, while those with two copies are at *significantly higher risk* of developing the disease.[24]

In addition to genetic factors, there are many **modifiable risks** that can be influenced by lifestyle and health conditions.[25] These include **diabetes**, **high blood pressure**, **obesity**, **smoking**, and **high cholesterol**. Poor **diet**, lack of **physical activity**, **social isolation**, and **low levels of education** are also linked to a greater chance of developing Alzheimer's. Chronic **stress**, **sleep disturbances**, and **depression** have recently gained attention as additional contributors. [26]

Understanding both *modifiable* and *non-modifiable* risk factors is essential for building **preventive strategies**, encouraging **early diagnosis**, and guiding **public health policies** aimed at reducing the global burden of Alzheimer's disease.[27]

Table 1: Key Risk Factors for Alzheimer's Disease [28-29]

Category	Risk Factor	Modifiable?
Age	Advancing age (especially over 65)	No
Genetic	APOE ε4, APP, PSEN1, PSEN2 mutations	No
Lifestyle	Smoking, poor diet, physical inactivity	Yes
Medical Conditions	Diabetes, hypertension, obesity, cholesterol	Yes
Psychosocial	Depression, social isolation, low education	Yes

3. Pathophysiology and Molecular Mechanisms

The progression of **Alzheimer's disease** is driven by a series of complex changes in the brain, many of which begin *years before symptoms appear*.[30] Two key features that define the disease are the buildup of **amyloid-beta plaques** and the formation of **tau tangles**.[31] These abnormal proteins interfere with communication between brain cells, eventually causing them to malfunction and die.[32]

The first change usually involves the overproduction or poor clearance of a protein fragment called **amyloid-beta**.[33] These fragments stick together, forming **sticky clumps** or **plaques** outside neurons. These plaques disrupt the normal communication between brain cells and trigger **inflammation**, which further damages brain tissue.[34] They also affect blood vessels, limit nutrient flow, and contribute to a toxic environment in the brain.[35]

As the disease advances, another protein called **tau** becomes abnormal. Normally, tau helps support the internal structure of neurons, but in Alzheimer's disease, it becomes **hyperphosphorylated** — meaning it changes shape and starts forming **tangles** inside neurons.[36] These *neurofibrillary tangles* block the transport of essential nutrients, leading to **cell breakdown** and death.[37]

Beyond plaques and tangles, several other factors play important roles. **Neuroinflammation** caused by the overactivation of immune cells in the brain — particularly *microglia* — contributes to the progression of damage.[38] These cells, meant to protect the brain, begin releasing harmful substances that worsen neuronal injury.

Additionally, **oxidative stress**, **mitochondrial dysfunction**, and **synaptic failure** are critical contributors. The brain cells become less efficient at producing energy, managing waste, and maintaining their structure, all of which accelerate their decline.[39]

Together, these pathological changes create a *vicious cycle* that leads to the progressive **loss of memory**, **judgment**, **language skills**, and eventually, control over basic bodily functions.[40] Understanding these mechanisms is essential for developing targeted treatments that can slow or stop the disease at its roots.[41]

Figure 2: Integrated Pathophysiology of Alzheimer's Disease



4. Clinical Features and Stages of Alzheimer's Disease

Alzheimer's disease develops slowly and progresses through several stages, each marked by increasing difficulties in **memory**, **thinking**, and **daily functioning**.[42] The changes are often subtle at first but gradually worsen, leading to complete dependence on others for care.[43]

The earliest stage is called **preclinical Alzheimer's**, where no outward symptoms are noticeable, but **biological changes** like amyloid buildup may already be happening in the brain.[45] This stage can last for years, and most people are unaware that the disease has started.

The next phase is **Mild Cognitive Impairment (MCI)** due to Alzheimer's disease. People in this stage may experience **slight memory problems**, such as forgetting recent conversations or misplacing items.[46] However, they are usually still able to live independently and function well in most daily tasks. Not all MCI cases lead to Alzheimer's, but this stage is considered a warning sign.[47]

As the condition progresses to **mild Alzheimer's**, individuals begin to show clear symptoms such as **frequent forgetfulness**, **difficulty finding words**, **trouble organizing thoughts**, or **getting lost in familiar places**.[48] They may struggle with managing finances, keeping appointments, or following instructions, but can often still manage personal hygiene and basic routines.[49]

In the **moderate stage**, symptoms become more noticeable and disruptive. People may forget **important life events**, **confuse people and places**, experience **mood swings**, or show **changes in behavior**, including **agitation** or **suspicion**.[50] Assistance becomes necessary for many daily activities, such as dressing or preparing meals.

Finally, in the **severe or late stage**, individuals lose the ability to **communicate clearly**, **recognize loved ones**, and eventually **control physical movements**. They may become bedridden, lose bladder and bowel control, and require **round-the-clock care**. This stage is emotionally difficult for both patients and families, as it marks a complete loss of independence.[51]

Each person's journey with Alzheimer's is different — the speed of progression and combination of symptoms can vary. However, understanding these stages is essential for providing **appropriate care**, making timely decisions, and planning for the future.[52]

Figure 3: Alzheimer's disease progression, highlighting how each clinical stage impacts an individual's daily life. From silent changes in the brain to complete dependence, the disorder affects both cognition and independence

. **Table 2: Clinical Stages of Alzheimer's Disease [53]**

Stage	Features
Preclinical	No symptoms; brain changes already occurring silently
Mild Cognitive Impairment	Mild memory issues; still mostly independent
Mild Stage	Forgetfulness, confusion, poor decision
making	
Moderate Stage	Behavioral changes, mood swings, help needed with daily tasks
Severe Stage	Total dependence, loss of speech and physical function

5. Diagnosis and Biomarkers

Diagnosing **Alzheimer's disease** can be challenging, especially in the early stages when symptoms may appear mild or overlap with other conditions.[54] A complete diagnosis usually requires a combination of **clinical evaluation**, **cognitive testing**, **brain imaging**, and, in some cases, **biomarker analysis**.[55]

The first step often involves a detailed **medical history** and discussion with the patient and close family members.[56] Doctors look for patterns of **memory loss**, changes in **behavior**, and difficulty in **problem-solving** or **language**.[57] Basic cognitive tests, such as the **Mini-Mental State Examination (MMSE)** or the **Montreal Cognitive Assessment (MoCA)**, are commonly used to evaluate mental functions.[58]

Neuroimaging plays a key role in identifying brain changes associated with Alzheimer's. **Magnetic Resonance Imaging (MRI)** helps detect brain shrinkage, especially in areas like the hippocampus, which is involved in memory.[59] **Computed Tomography (CT)** scans can also show structural changes, although with less detail. In more advanced cases, **Positron Emission Tomography (PET)** scans may be used to detect abnormal buildups of amyloid or tau proteins in the brain.[60]

In recent years, **biomarkers** have gained importance for early and more accurate diagnosis. These are measurable substances in the body that reflect the disease process.[61] In Alzheimer's, key biomarkers include **low levels of amyloid-beta** and **high levels of tau** or **phosphorylated tau** in **cerebrospinal fluid (CSF)**.[62] These findings suggest that brain cells are being damaged even before major symptoms appear.

Blood-based biomarkers are also being developed as a **less invasive** and **more accessible** method for screening. These could soon become a valuable tool in identifying people at risk, especially in large-scale community settings.[63]

Importantly, a proper diagnosis also involves **ruling out other causes** of memory problems, such as **vitamin deficiencies**, **thyroid disorders**, **depression**, or other types of dementia. Alzheimer's disease shares overlapping features with conditions like **vascular dementia**, **Lewy body dementia**, and **frontotemporal dementia**, so careful evaluation is necessary.[64]

Early diagnosis not only gives patients and families time to plan but also opens doors to **clinical trials** and **treatment options** that may help slow the disease's progression.[65]

Figure 4: Flow of Alzheimer's Disease Biomarkers From Sample Type to Diagnostic Insight



Table 3: Common Biomarkers Used in Alzheimer's Diagnosis [66-67]

Biomarker Type	Example	What It Indicates
Amyloid markers	Amyloid-beta 42 (CSF, PET scan)	Early plaque buildup in brain
Tau markers	Total tau, phosphorylated tau	Neuronal injury and disease stage
Neurodegeneration	MRI (hippocampal shrinkage)	Brain cell loss and atrophy
Inflammation markers	YKL-40, cytokines	Chronic brain inflammation
Blood-based biomarkers	Plasma Aβ42/40 ratio, p-tau	Early and accessible diagnostic option

6. Current and Emerging Therapies

Although there is no cure for **Alzheimer's disease**, several treatments are available to help manage symptoms and improve quality of life.Therapies are generally divided into two types: **symptomatic treatments**, which ease the effects of the disease, and **emerging diseasemodifying therapies**, which aim to slow or alter the progression of brain damage.[68]

a. Symptomatic Treatments

The most commonly prescribed medications are those that boost communication between brain cells by increasing the levels of certain neurotransmitters.[69] **Cholinesterase inhibitors**, such as donepezil, rivastigmine, and galantamine, help improve memory and thinking in mild to moderate stages. Another drug called **memantine** works differently by regulating glutamate, a chemical involved in learning and memory, and is often used in moderate to severe cases.[70]

While these drugs don't stop the disease from progressing, they can offer **temporary improvements** in cognition, mood, or behavior, helping patients maintain independence for a longer time.[71]

b. Disease-Modifying Therapies

In recent years, researchers have shifted their focus toward therapies that target the **underlying causes** of Alzheimer's rather than just the symptoms.[72] One promising area is the development of drugs that target **amyloid-beta plaques**, which are believed to play a central role in disease progression. Some newly approved treatments, such as **monoclonal antibodies**, aim to clear amyloid from the brain and potentially slow cognitive decline.[73]

Scientists are also exploring drugs that target **tau protein tangles**, **neuroinflammation**, and **oxidative stress**. Though these therapies are still under investigation, they represent an important step toward changing the course of the disease.[74]

c. Non-Pharmacological Interventions

In addition to medication, **lifestyle modifications** and **supportive therapies** play a vital role in managing Alzheimer's. Regular **physical activity**, a **healthy diet**, and **mental stimulation** can help maintain brain function.[75] Engaging in meaningful activities, maintaining **social connections**, and ensuring a **stable daily routine** are also helpful in reducing anxiety and confusion in patients.[76]

Cognitive training, **occupational therapy**, and **caregiver support** are essential tools in longterm management. A supportive environment can greatly improve a person's ability to function and feel safe.[77]
As research continues, the goal is to find combinations of drug and lifestyle therapies that not only treat the symptoms but also prevent or delay the onset of Alzheimer's disease altogether. [78]

Figure 5: Integrated Approaches to Alzheimer's Disease Treatment

Table 4: Current and Emerging Therapies for Alzheimer's Disease [78]

Therapy Type	Examples	Purpose
Cholinesterase Inhibitors	Donepezil, Rivastigmine	Boost cognition
NMDA Antagonist	Memantine	Helps in moderate to severe stages
Monoclonal Antibodies	Aducanumab, lecanemab	Target amyloid plaques
Lifestyle Interventions	Exercise, diet, mental activities	Delay symptoms and support brain health

d. Management Strategies and Supportive Care

Management of Alzheimer's extends beyond medications. A comprehensive care approach includes **physical safety**, **emotional support**, and **routine structure** for patients at every stage.[79]
Interventions must adapt to the severity of symptoms:

- In the **preclinical stage**, focus is placed on **lifestyle modifications** like exercise, sleep, and cognitive enrichment.[80]
- In **early stages**, interventions such as **cognitive training** and **medications** may help preserve function. [81]
- As symptoms progress to **moderate and severe stages**, greater emphasis is placed on **behavioral support**, **environmental adaptations**, and **caregiver involvement**.[82]
- For **advanced cases**, **palliative care**, 24/7 supervision, and emotional reassurance are crucial. [83]

Providing care tailored to disease stage improves patient dignity, safety, and **overall quality of life**.

Figure 6: Alzheimer's Disease Progression and Stage-Specific Interventions



7. Preventive Approaches and Risk Reduction

Although Alzheimer's disease is not fully preventable, growing evidence suggests that **lifestyle choices and risk factor control** can significantly **reduce the likelihood** or **delay the onset** of cognitive decline.

a. Physical Health engaging in **regular physical activity**, such as walking, yoga, or swimming, enhances **blood flow to the brain** and supports **neuroplasticity**. Prioritizing **good sleep hygiene** and managing **cardiovascular health** are essential for maintaining brain resilience.**[83]**

b. Nutritional Factors

A **Mediterranean-style diet** rich in leafy greens, fruits, fish, nuts, and olive oil has been linked to a **lower risk of dementia**.[84] Nutrients such as **omega-3 fatty acids**, **antioxidants**, and **vitamin D** are thought to protect brain cells from damage.[85]

c. Cognitive Engagement

Keeping the mind active through **lifelong learning**, **reading**, **puzzles**, and **memory exercises** can help build **cognitive reserve**, allowing the brain to compensate for damage longer.[86]

d. Social Connection

Maintaining **strong social ties** through conversations, group activities, or volunteering may help **reduce loneliness**, stress, and **mental decline**. Social engagement supports **emotional wellbeing** and cognitive performance.[87]

e. Risk Factor Management

Controlling chronic health issues such as **hypertension**, **diabetes**, and **high cholesterol** can reduce vascular contributions to dementia. Quitting smoking and limiting alcohol intake also lower brain-related risks.[88]

8. Future Directions in Alzheimer's Research

As science continues to unravel the complexity of **Alzheimer's disease**, researchers are moving beyond traditional approaches to explore **innovative strategies** that could transform diagnosis, treatment, and prevention.[89] The future of Alzheimer's care lies in **early detection**, **personalized medicine**, and **multitargeted therapies**.[90]

One major goal is to detect Alzheimer's **before symptoms appear**. New tools such as **bloodbased biomarkers**, **genetic risk profiling**, and **advanced brain imaging** may allow doctors to identify individuals at risk much earlier than before.[91] Early diagnosis gives patients and families more time to plan and opens the door to **preventive treatments** before significant brain damage occurs.[92]

Another exciting area is **personalized or precision medicine**. Instead of using the same treatment for everyone, researchers are working on therapies that are tailored to a person's **genetic makeup**, **biomarker levels**, and **lifestyle factors**.[93] This approach could lead to more effective results with fewer side effects.

Future therapies are also being designed to go beyond amyloid and tau. Scientists are now exploring **immune system modulators**, **neuroprotective agents**, and even **stem cell therapies** that could regenerate damaged brain tissue.[94] Some studies are investigating the potential of **gene editing** tools like CRISPR to repair or block the faulty genes involved in Alzheimer's.

Artificial intelligence (AI) and **digital health tools** are also being developed to track early behavioral changes and help monitor disease progression remotely. These technologies may assist in predicting who is most likely to develop Alzheimer's and how fast it will progress.[95]

Public health efforts are expected to focus more on **risk reduction**, encouraging healthy aging through **education**, **diet**, **exercise**, **stress management**, and **social engagement** — all of which have shown protective effects on brain health.

Although challenges remain, the future holds promise. Continued research, increased funding, and greater global awareness are bringing us closer to finding **effective, long-term solutions** to one of the most pressing neurological challenges of our time.[96]

Table 5: Future Therapeutic Approaches Under Investigation

Therapy Focus	Strategy	Goal
Immunotherapy	Anti-amyloid and anti-tau vaccines	Remove or block toxic proteins
Gene Editing	CRISPR, antisense oligonucleotides	Fix or silence faulty genes
Neuroprotection	Antioxidants, mitochondrial boosters	Prevent further brain cell damage
Stem Cell Therapy	Neural stem cell replacement	Regenerate damaged neurons
Digital & AI Tools	Apps, sensors, digital monitoring	Predict, track, and personalize care

9. Conclusion

Alzheimer's disease remains one of the most complex and devastating disorders affecting the aging population. It slowly erodes a person's ability to think, remember, and live independently, placing a tremendous burden not only on the individual but also on families, caregivers, and healthcare systems worldwide.

While current treatments offer only temporary relief from symptoms, advances in our understanding of the disease's **biological mechanisms** have opened new possibilities for **early detection**, **personalized care**, and **disease-modifying therapies**. Researchers are now focusing on identifying the condition in its earliest stages, intervening before irreversible brain damage occurs.

Prevention strategies that promote **brain-healthy lifestyles**, including a **balanced diet**, **physical activity**, **mental stimulation**, and **social engagement**, are gaining importance as low-cost, accessible ways to reduce risk. At the same time, exciting developments in **biomarkers**, **genetics**, and **innovative therapies** offer hope for more effective future treatments.

Although we still have a long way to go, growing awareness and dedicated research efforts are steadily moving us closer to better outcomes for those affected. By combining science, compassion, and public action, we can improve the lives of millions and work toward a future where Alzheimer's is no longer a feared diagnosis — but a manageable condition, or even one day, a preventable one.

References

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2016 Apr 1;12(4):459-509.

2.Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. The Lancet Neurology. 2010 Aug 1;9(8):793-806.

3. Sullivan AB, Miller D. Who is taking care of the caregiver?. Journal of patient experience. 2015 May;2(1):7-12.

4. Möller HJ, Graeber MB. The case described by Alois Alzheimer in 1911: historical and conceptual perspectives based on the clinical record and neurohistological sections. European archives of psychiatry and clinical neuroscience. 1998 Jul;248:111-22.

5. Goedert M. Oskar Fischer and the study of dementia. Brain. 2009 Apr 1;132(4):1102-11.

6. Kelly EB. Alzheimer's disease. Infobase Publishing; 2008.

7. Kovacs GG. Molecular pathology of neurodegenerative diseases: principles and practice. Journal of clinical pathology. 2019 Nov 1;72(11):725-35.

8. Javaid SF, Giebel C, Khan MA, Hashim MJ. Epidemiology of Alzheimer's disease and other dementias: Rising global burden and forecasted trends. F1000Research. 2021 May 27;10:425.

9. Bloom DE, Boersch-Supan A, McGee P, Seike A. Population aging: facts, challenges, and responses. Benefits and compensation International. 2011 May;41(1):22.

10. The disease not only places a heavy *emotional toll* on families but also leads to enormous **financial costs** for healthcare systems.

11. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC. Heart failure: preventing disease and death worldwide. ESC heart failure. 2014 Sep;1(1):4-25.

12. Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack Jr CR, Jagust W, Morris JC, Petersen RC. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia. 2019 Jan 1;15(1):106-52.

13. Aronowitz RA. When do symptoms become a disease?. Annals of internal medicine. 2001 May 1;134(9_Part_2):803-8.

14. Volkow ND. Drugs, brains, and behavior: The science of addiction. Retrieved on March. 2010;23(2011):255-169.

15. Jurcău MC, Andronie-Cioara FL, Jurcău A, Marcu F, Ţiț DM, Pașcalău N, Nistor-Cseppentö DC. The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer's disease: therapeutic implications and future perspectives. Antioxidants. 2022 Oct 31;11(11):2167.

16. Croft P, Altman DG, Deeks JJ, Dunn KM, Hay AD, Hemingway H, LeResche L, Peat G, Perel P, Petersen SE, Riley RD. The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice. BMC medicine. 2015 Dec;13:1-8.

17. World Health Organization. Managing epidemics: key facts about major deadly diseases. World Health Organization; 2023 Nov 14.

18. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2016 Apr 1;12(4):459-509.

19. Cohen JE. World population in 2050: assessing the projections. InConference Series-Federal Reserve Bank of Boston 2001 Nov (Vol. 46, pp. 83-113). Federal Reserve Bank of Boston; 1998.

20. Kuo CY, Stachiv I, Nikolai T. Association of late life depression,(non-) modifiable risk and protective factors with dementia and Alzheimer's disease: literature review on current evidences, preventive interventions and possible future trends in prevention and treatment of dementia. International journal of environmental research and public health. 2020 Oct;17(20):7475.

21. Andrew MK, Tierney MC. The puzzle of sex, gender and Alzheimer's disease: Why are women more often affected than men?. Women's Health. 2018 Dec;14:1745506518817995.

22. Ryan NS, Nicholas JM, Weston PS, Liang Y, Lashley T, Guerreiro R, Adamson G, Kenny J, Beck J, Chavez-Gutierrez L, De Strooper B. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. The Lancet Neurology. 2016 Dec 1;15(13):1326-35.

23. van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele. The Lancet Neurology. 2011 Mar 1;10(3):280-8.

24. Fanciulli M, Petretto E, Aitman TJ. Gene copy number variation and common human disease. Clinical genetics. 2010 Mar;77(3):201-13.

25. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature Reviews Neurology. 2017 Jan;13(1):25-36.

26. Wei M, Mitchell BD, Haffner SM, Stem MP. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans: the San Antonio Heart Study. American journal of epidemiology. 1996 Dec 1;144(11):1058-65.

27. Kuo CY, Stachiv I, Nikolai T. Association of late life depression,(non-) modifiable risk and protective factors with dementia and Alzheimer's disease: literature review on current evidences, preventive interventions and possible future trends in prevention and treatment of dementia. International journal of environmental research and public health. 2020 Oct;17(20):7475.

28. Armstrong RA. Risk factors for Alzheimer's disease. Folia neuropathologica. 2019 Jan 1;57(2):87-105.

29. Silva MV, Loures CD, Alves LC, De Souza LC, Borges KB, Carvalho MD. Alzheimer's disease: risk factors and potentially protective measures. Journal of biomedical science. 2019 Dec;26:1-1.

30. Lloret A, Esteve D, Lloret MA, Cervera-Ferri A, Lopez B, Nepomuceno M, Monllor P. When does Alzheimer′ s disease really start? The role of biomarkers. International journal of molecular sciences. 2019 Nov 6;20(22):5536.

31. Gallardo G, Holtzman DM. Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. Tau Biology. 2020 Feb 25:187-203.

32. Lipton P. Ischemic cell death in brain neurons. Physiological reviews. 1999 Jan 10.

33. J Baranello R, L Bharani K, Padmaraju V, Chopra N, K Lahiri D, H Greig N, A Pappolla M, Sambamurti K. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Current Alzheimer Research. 2015 Jan 1;12(1):32-46.

34. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. Journal of internal medicine. 2015 Nov;278(5):483-93.\

35. Paulson OB. Blood–brain barrier, brain metabolism and cerebral blood flow. European Neuropsychopharmacology. 2002 Dec 1;12(6):495-501.

36. Iqbal K, Alonso AD, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H. Tau pathology in Alzheimer disease and other tauopathies. Biochimica et Biophysica Acta (BBA)-molecular basis of Disease. 2005 Jan 3;1739(2-3):198-210.

37. Brion JP. Neurofibrillary tangles and Alzheimer's disease. European neurology. 1998 Oct 14;40(3):130-40.

38. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal transduction and targeted therapy. 2023 Jul 12;8(1):267.

39. Błaszczyk JW. Energy metabolism decline in the aging brain—pathogenesis of neurodegenerative disorders. Metabolites. 2020 Nov 7;10(11):450.

40. Arnold SE, Kumar A. Reversible dementias. Medical Clinics of North America. 1993 Jan 1;77(1):215-30.

41. Pascale A, Proietti S, Pantelides IS, Stringlis IA. Modulation of the root microbiome by plant molecules: the basis for targeted disease suppression and plant growth promotion. Frontiers in plant science. 2020 Jan 24;10:1741.

42. Zvěřová M. Clinical aspects of Alzheimer's disease. Clinical biochemistry. 2019 Oct 1;72:3-6.

43. Dartington T. Managing vulnerability: The underlying dynamics of systems of care. Routledge; 2018 Oct 8.

44. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. Journal of Alzheimer's Disease. 2012 Dec 27;33(s1):S405-16.

45. McIntosh J. PATIENTS'AWARENESS AND DESIRE FOR INFORMATION ABOUT DIAGNOSED BUT UNDISCLOSED MALIGNANT DISEASE. The Lancet. 1976 Aug 7;308(7980):300-3.

46. Almkvist O, Basun H, Bäckman L, Herlitz A, Lannfelt L, Small B, Viitanen M, Wahlund LO, Winblad B. Mild cognitive impairment—an early stage of Alzheimer's disease?. Springer Vienna; 1998.

47. Morris JC. Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Archives of neurology. 2006 Jan 1;63(1):15-6.

48. Bature F, Guinn BA, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer's disease: a systematic scoping review of literature from 1937 to 2016. BMJ open. 2017 Aug 1;7(8):e015746.

49. Crooks VA. "Because everything changes that day; you don't do the routine": Alterations and activities chronically ill women undertake on days with health care provider appointments. Chronic illness. 2015 Dec;11(4):267-78.

50. Schildkrout B. Masquerading symptoms: Uncovering physical illnesses that present as psychological problems. John Wiley & Sons; 2014 May 5.

51. Stroebe W, Stroebe MS. Bereavement and health: The psychological and physical consequences of partner loss.

52. Ashworth RM. Experiences of Early and Late-Onset Alzheimer's Disease: Perceptions of Stigma and Future Outlook.

53. Reisberg B, Franssen EH. Clinical stages of Alzheimer's disease. An atlas of Alzheimer's disease. 1999:11-20.

54. Ausó E, Gómez-Vicente V, Esquiva G. Biomarkers for Alzheimer's disease early diagnosis. Journal of Personalized Medicine. 2020 Sep;10(3):114.

55. Sabbagh MN, Lue LF, Fayard D, Shi J. Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data. Neurology and therapy. 2017 Jul;6:83-95.

56. Bennett RL. The practical guide to the genetic family history. John Wiley & Sons; 2011 Sep 20.

57. Cutler P. Problem solving in clinical medicine: From data to diagnosis. Lippincott Williams & Wilkins; 1998.

58. Eva KW. The aging physician: changes in cognitive processing and their impact on medical practice. Academic Medicine. 2002 Oct 1;77(10):S1-6.

59. Wierenga CE, Bondi MW. Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease. Neuropsychology review. 2007 Jun;17:127-43.

60. Ariza M, Kolb HC, Moechars D, Rombouts F, Andrés JI. Tau positron emission tomography (PET) imaging: past, present, and future. Journal of Medicinal Chemistry. 2015 Jun 11;58(11):4365-82.

61. Ahmad A, Imran M, Ahsan H. Biomarkers as biomedical bioindicators: Approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics. 2023 May 31;15(6):1630.

62. Wallin ÅK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer's disease: Levels of β-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dementia and geriatric cognitive disorders. 2006 Feb 6;21(3):131-8.

63. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nature reviews Clinical oncology. 2011 Mar;8(3):142-50.

64. Mast BT, Yochim BP. Alzheimer's disease and dementia. Hogrefe Publishing GmbH; 2018 Mar 21.

65. World Health Organization. Diagnosis and treatment. World Health Organization; 2008.

66. Mantzavinos V, Alexiou A. Biomarkers for Alzheimer's disease diagnosis. Current Alzheimer Research. 2017 Nov 1;14(11):1149-54.

67. Khoury R, Ghossoub E. Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review. Biomarkers in Neuropsychiatry. 2019 Dec 1;1:100005.

68. Bramlett HM, Dietrich WD. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Progress in brain research. 2007 Jan 1;161:125-41.

69. Lovinger DM. Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol. Alcohol Research & Health. 2008;31(3):196.

70. Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer's disease. Drugs & aging. 2015 Jul;32:537-47.

71. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. The Journal of the American Board of Family Medicine. 2012 May 1;25(3):350-66.

72. Selkoe DJ. The therapeutics of Alzheimer's disease: where we stand and where we are heading. Annals of neurology. 2013 Sep;74(3):328-36.

73. Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics. Drugs. 2023 May;83(7):569-76.

74. Fišar Z. Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer's disease and identifying promising drug targets. Biomolecules. 2022 Nov 11;12(11):1676.

75. Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for prevention and treatment of Alzheimer's disease. BioMed research international. 2016;2016(1):2589276.

76. Van Orden KA, Bower E, Lutz J, Silva C, Gallegos AM, Podgorski CA, Santos EJ, Conwell Y. Strategies to promote social connections among older adults during "social distancing" restrictions. The American Journal of Geriatric Psychiatry. 2021 Aug 1;29(8):816-27.

77. Thinnes A, Padilla R. Effect of educational and supportive strategies on the ability of caregivers of people with dementia to maintain participation in that role. The American journal of occupational therapy. 2011 Sep 1;65(5):541-9.

78. Nygaard HB. Current and emerging therapies for Alzheimer's disease. Clinical therapeutics. 2013 Oct 1;35(10):1480-9.

79. Grossberg GT, Desai AK. Management of Alzheimer's disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2003 Apr 1;58(4):M331-53.

80. Queen NJ, Hassan QN, Cao L. Improvements to healthspan through environmental enrichment and lifestyle interventions: where are we now?. Frontiers in Neuroscience. 2020 Jun 12;14:605.

81. Butler M, McCreedy E, Nelson VA, Desai P, Ratner E, Fink HA, Hemmy LS, McCarten JR, Barclay TR, Brasure M, Davila H. Does cognitive training prevent cognitive decline? A systematic review. Annals of internal medicine. 2018 Jan 2;168(1):63-8.

82. De Vugt ME, Verhey FR. The impact of early dementia diagnosis and intervention on informal caregivers. Progress in neurobiology. 2013 Nov 1;110:54-62.

83. Clemente-Suárez VJ, Martín-Rodríguez A, Curiel-Regueros A, Rubio-Zarapuz A, Tornero-Aguilera JF. Neuro-nutrition and exercise synergy: exploring the bioengineering of cognitive enhancement and mental health optimization. Bioengineering. 2025 Feb 19;12(2):208.

84. Farooqui T, Farooqui AA, editors. Role of the Mediterranean diet in the brain and neurodegenerative diseases. Academic Press; 2017 Oct 24.

85. Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007 Jan 30;31(1):12-26.

86. La Rue A. Healthy brain aging: role of cognitive reserve, cognitive stimulation, and cognitive exercises. Clinics in geriatric medicine. 2010 Feb 1;26(1):99-111.

87. Kelly ME, Duff H, Kelly S, McHugh Power JE, Brennan S, Lawlor BA, Loughrey DG. The impact of social activities, social networks, social support and social relationships on the cognitive functioning of healthy older adults: a systematic review. Systematic reviews. 2017 Dec;6:1-8.

88. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert review of neurotherapeutics. 2011 May 1;11(5):677-708.

89. Juganavar A, Joshi A, Shegekar T. Navigating early Alzheimer's diagnosis: a comprehensive review of diagnostic innovations. Cureus. 2023 Sep 9;15(9).

90. Di Meco A, Vassar R. Early detection and personalized medicine: future strategies against Alzheimer's disease. Progress in molecular biology and translational science. 2021 Jan 1;177:157-73.

91. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology. 2018 Nov;14(11):639-52.

92. Salander P, Bergenheim AT, Hamberg K, Henriksson R. Pathways from symptoms to medical care: a descriptive study of symptom development and obstacles to early diagnosis in brain tumour patients. Family Practice. 1999 Apr 1;16(2):143-8.

93. Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers. 2023 Jan;15(15):3837.

94. Vasic V, Barth K, Schmidt MH. Neurodegeneration and neuro-regeneration—Alzheimer's disease and stem cell therapy. International journal of molecular sciences. 2019 Aug 31;20(17):4272.

95. Lyall DM, Kormilitzin A, Lancaster C, Sousa J, Petermann-Rocha F, Buckley C, Harshfield EL, Iveson MH, Madan CR, McArdle R, Newby D. Artificial intelligence for dementia—Applied models and digital health. Alzheimer's & Dementia. 2023 Dec;19(12):5872-84.

96. Dogra S, Dunstan DW, Sugiyama T, Stathi A, Gardiner PA, Owen N. Active aging and public health: evidence, implications, and opportunities. Annual review of public health. 2022 Apr 5;43(1):439-59.